T-Cell Receptor Discovery and Engineering Platform
Our innovative T-Cell Receptor (TCR) technology platform is enabling the fast and efficient discovery and qualification of a large number of high-affinity and high-specificity TCRs that can be used for Adoptive Cell Therapies i.e. ACTengine® and ACTallo® and TCER® - Bispecific TCR Molecule development.
T-Cell Receptor Discovery
- pHLA target-restricted TCRs are identified in high throughput from primary human PBMC samples, possible for several targets in parallel.
- TCRs are re-expressed and qualified as candidates for adoptive cellular therapies or a bispecific TCR approach.
- Qualified TCRs are subject to further development, including affinity maturation.
In addition, Immatics has established powerful capabilities in TCR engineering, generating TCRs with affinities within the low nM range, while retaining the molecules natural specificity. The resulting ultra-high-affinity TCRs are utilized for soluble formats such as TCER®s, Immatics Bispecific TCRs.